Westchester Capital Management (Nebraska)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-75
Closed -$5.4K 47
2022
Q4
$5.4K Hold
75
﹤0.01% 44
2022
Q3
$5K Hold
75
﹤0.01% 46
2022
Q2
$6K Hold
75
﹤0.01% 48
2022
Q1
$5K Hold
75
﹤0.01% 46
2021
Q4
$5K Hold
75
﹤0.01% 44
2021
Q3
$4K Hold
75
﹤0.01% 46
2021
Q2
$5K Hold
75
﹤0.01% 43
2021
Q1
$5K Buy
+75
New +$4.67K ﹤0.01% 46
2020
Q2
Sell
-587
Closed -$33K 42
2020
Q1
$33K Hold
587
0.01% 37
2019
Q4
$38K Buy
+587
New +$33.6K 0.01% 38

Other funds holding BMY

Westchester Capital Management (Nebraska)'s BMY Position: Q1 2023 in Review

Westchester Capital Management (Nebraska) sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 75 shares — an estimated $5.4K sold.

Westchester Capital Management (Nebraska) first reported a position in BMY in Q4 2019 and held it in 10 quarters. The position peaked at $38K in Q4 2019. 2,541 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

  • Westchester Capital Management (Nebraska) reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
  • Westchester Capital Management (Nebraska) sold 75 Bristol-Myers Squibb shares in Q1 2023, an estimated $5.4K.
  • Westchester Capital Management (Nebraska) first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 10 quarters.
  • Westchester Capital Management (Nebraska)'s Bristol-Myers Squibb position peaked at $38K in Q4 2019.
  • 2,541 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Westchester Capital Management (Nebraska)'s 13F filing for Q1 2023, filed 15 May 2023.